Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Proposes 510(k) Requirements For Tanning Beds

This article was originally published in The Gray Sheet

Executive Summary

The agency issued a proposed order reclassifying tanning beds from class I to class II with 510(k) requirements, and is proposing strict warnings against use in children under age 18.

You may also be interested in...



UDI Final Rule Listed For July Release In HHS Regulatory Agenda

The UDI final rule is among 11 device-focused proposed and final regulations included in the HHS unified agenda of regulations planned through early 2014, and it is likely the most closely watched of the group by industry.

House Panel Approves FDA Funding Bill With $6 Mil. Cut For Device Programs

The House Appropriations Committee approved the fiscal year 2013 Agriculture/FDA funding bill June 19, including $317 million in appropriations for device oversight activities, $2 million shy of what the counterpart Senate committee passed in April.

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT032031

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel